期刊
JOURNAL OF MOLECULAR DIAGNOSTICS
卷 24, 期 12, 页码 1279-1291出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmoldx.2022.09.009
关键词
-
类别
资金
- Illumina
- Asuragen
- Qiagen
- Perkin Elmer Inc.
- Bionano Genomics
- Agena
- Agendia
- PGDx
- Thermo Fisher Scientific
- Cepheid
- BMS
This study demonstrates the utility of optical genome mapping (OGM) as a new technology for better characterization of hematological malignancies, including revealing the genetic complexity of tumors, with high technical performance and concordance. OGM has the potential to be a first-tier cytogenomic test for hematologic malignancies.
The current standard-of-care cytogenetic techniques for the analysis of hematological malignancies include karyotyping, fluorescence in situ hybridization, and chromosomal microarray, which are labor intensive and time and cost prohibitive, and they often do not reveal the genetic complexity of the tumor, demonstrating the need for alternative technology for better characterization of these tumors. Herein, we report the results from our clinical validation study and demonstrate the utility of optical genome mapping (OGM), evaluated using 92 sample runs (including replicates) that included 69 well -characterized unique samples (59 hematological neoplasms and 10 controls). The technical performance (quality control metrics) resulted in 100% first-pass rate, with analytical performance (concordance) showing a sensitivity of 98.7%, a specificity of 100%, and an accuracy of 99.2%. OGM demonstrated robust technical, analytical performance, and interrun, intrarun, and interinstrument reproducibility. The limit of detection was determined to be at 5% allele fraction for aneuploidy, translocation, interstitial deletion, and duplication. OGM identified several additional structural variations, revealing the genomic architecture in these neoplasms that provides an opportunity for better tumor classifi-cation, prognostication, risk stratification, and therapy selection. Overall, OGM has outperformed the standard-of-care tests in this study and demonstrated its potential as a first-tier cytogenomic test for hematologic malignancies. (J Mol Diagn 2022, 24: 1279-1291; https://doi.org/10.1016/ j.jmoldx.2022.09.009)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据